side
effect
interferonribavirin
combin
therapi
limit
sustain
viral
respons
achiev
hepat
c
viru
hcv
patient
coupl
ribavirin
macromolecular
carrier
target
drug
liver
would
reduc
system
complic
aim
studi
evalu
efficaci
hemoglobinribavirin
conjug
hrc
murin
hepat
viru
strain
induc
viral
hepat
hrc
greater
antivir
activ
isol
hepatocyt
macrophag
wherea
ribavirin
hrc
inhibit
product
proinflammatori
cytokin
interferon
gamma
tumor
necrosi
factor
alpha
macrophag
vivo
untreat
mice
develop
clinic
biochem
sign
acut
viral
hepat
die
day
post
infect
liver
recov
untreat
infect
mice
show
greater
necrosi
contrast
surviv
enhanc
ribavirinand
hrc
mice
mark
reduct
biochem
alt
max
iul
ribavirin
iul
hrc
histolog
evid
hepat
necrosi
ribavirinhrc
vs
untreat
control
clinic
hrc
mice
behav
normal
contrast
ribavirintr
mice
develop
lethargi
abnorm
fur
textur
conclus
target
deliveri
ribavirin
liver
alter
cours
infect
demonstr
prolong
surviv
improv
behavior
reduc
sign
histolog
evid
diseas
well
inhibit
viral
replic
product
inflammatori
cytokin
vitro
hepatolog
macrophag
periton
macrophag
harvest
balbcj
mice
day
intraperiton
inject
ml
thioglycol
difco
laboratori
detroit
mi
describ
macrophag
resuspend
rpmi
icn
biomed
costa
mesa
ca
supplement
mmoll
glutamin
sigma
chemic
st
loui
mo
heatinactiv
fb
flow
laboratori
mississauga
ontario
canada
macrophag
pure
determin
morpholog
nonspecif
esteras
stain
viabil
exceed
trypan
blue
exclus
c
hronic
hepat
c
viru
hcv
infect
major
public
health
problem
affect
million
peopl
unit
state
million
individu
worldwid
addit
chronic
hcv
caus
factor
approxim
case
hepatocellular
carcinoma
unit
state
singl
common
indic
orthotop
liver
transplant
worldwid
howev
treatment
hcv
infect
remain
problemat
current
standard
care
combin
interferon
alpha
ribavirin
combin
treatment
limit
sever
side
effect
often
lead
prematur
cessat
therapi
major
toxic
associ
ribavirin
dosedepend
hemolyt
anemia
occur
approxim
treat
individu
result
ribavirin
dose
reduct
develop
anemia
usual
start
week
therapi
precipit
coupl
ribavirin
carrier
molecul
offer
potenti
therapeut
improv
safeti
efficaci
target
drug
deliveri
ribavirin
key
tissu
infect
hcv
prevent
hemolyt
anemia
caus
exposur
red
blood
cell
free
ribavirin
target
drug
attach
carrier
molecul
deliveri
specif
tissu
via
receptormedi
endocytosi
recent
establish
method
improv
efficaci
decreas
toxic
side
effect
provid
altern
problemat
system
drug
therapi
acellular
hemoglobin
hb
rapidli
bound
haptoglobin
hp
vivo
taken
cell
bear
receptor
hbhp
complex
princip
macrophag
kupffer
cell
hepatocyt
natur
pathway
hb
clearanc
hbhp
scaveng
receptor
identifi
marker
cell
monocytemacrophag
lineag
level
receptor
increas
liver
patient
acut
hepat
hrc
conjug
human
hemoglobin
ribavirin
bound
haptoglobin
hphbrv
design
deliv
ribavirin
liver
avoid
system
toxic
associ
chronic
ribavirin
therapi
select
uptak
hbhp
complex
mediat
bind
complex
receptor
follow
entri
lysosom
receptormedi
bind
uptak
hrc
demonstr
model
cell
express
hbhp
receptor
acid
phosphatas
lysosom
enzym
shown
releas
bioactiv
ribavirin
hrc
vitro
similar
releas
activ
drug
expect
lysosom
uptak
conjug
target
cell
vivo
multipl
ribavirin
molecul
conjug
hb
molecul
therefor
hrc
potenti
achiev
higher
intracellular
dose
ribavirin
target
tissu
current
feasibl
estim
compar
liver
concentr
could
achiev
exceed
administ
endogen
hpsatur
dose
hbribavirin
order
g
hb
hrc
may
effect
maintain
optim
ribavirin
level
hcv
patient
would
otherwis
requir
dose
reduct
discontinu
ribavirin
therapi
system
consequ
aim
studi
evalu
effect
hrc
mous
model
viral
hepat
induc
coronaviru
largest
coronaviru
famili
positivestrand
rna
virus
genom
size
kb
cap
structur
poli
tail
replic
liverderiv
macrophag
kupffer
cell
endotheli
cell
parenchym
cell
hepatocyt
higher
degre
replic
macrophag
reservoir
viral
replic
macrophag
appear
prerequisit
gain
access
hepatocyt
viral
infect
macrophag
lead
mark
inflammatori
respons
associ
cellular
immun
respons
product
nonneutr
antibodi
respons
fail
control
viral
replic
induct
proinflammatori
mediat
tumor
necrosi
factor
alpha
activ
endotheli
cell
increas
express
adhes
molecul
result
recruit
inflammatori
cell
vasoconstrict
intravascular
thrombosi
fibrin
deposit
liver
necrosi
within
day
postinfect
fulmin
hepat
failur
result
lead
death
infect
mice
current
studi
design
examin
potenti
hrc
treat
infect
antivir
antiinflammatori
pathway
hrc
hrc
prepar
describ
ribavirin
interchem
shenzen
china
phosphatebuff
salin
pb
phosphoryl
group
accord
establish
method
subsequ
activ
phosphorimidazolid
accord
method
fium
et
al
ribavirinphosphorimidazolid
react
excess
human
carbonmonoxyhemoglobin
hemosol
corp
mississauga
ontario
canada
moll
sodium
bicarbon
buffer
ph
result
phosphoramid
attach
protein
amino
group
molar
drug
ratio
hemoglobinribavirin
hbrv
conjug
determin
ribavirin
molecul
per
hemoglobin
littl
unmodifi
hemoglobin
remain
hour
reaction
hbrv
conjug
extens
dialyz
pb
complet
reaction
purifi
rat
haptoglobin
incub
hbrv
pb
form
hrc
complex
subsequ
purifi
prepar
asept
sizeexclus
chromatographi
remov
unbound
hbrv
final
product
diafilt
pb
concentr
mgml
total
protein
viru
obtain
american
type
cultur
collect
rockvil
md
plaqu
purifi
monolay
dbtcell
grown
titer
plaqueform
unit
pfu
ml
cell
viru
harvest
centrifug
hour
assay
monolay
cell
standard
plaqu
assay
hepatocyt
hepatocyt
isol
liver
balbcj
mice
previous
describ
briefli
mice
anesthet
intraperiton
inject
pentobarbit
g
bodi
weight
abdomen
open
midlin
incis
portal
vein
expos
cannul
silast
tube
liver
perfus
oxygen
co
calciumand
magnesiumfre
hank
balanc
salt
solut
hbss
flow
rate
mlmin
minut
perfus
chang
hbss
calcium
magnesium
collagenas
b
dnase
minut
liver
remov
place
steril
petri
dish
contain
cold
hbss
fb
liver
cell
dispers
cellular
suspens
centrifug
minut
twice
cell
pellet
resuspend
ml
hbss
centrifug
minut
cell
count
resuspend
concentr
ml
complet
rpmi
fortifi
fb
viabil
hepatocyt
preand
posttreat
assess
trypan
blue
stain
puriti
hepatocyt
judg
absenc
immunofluoresc
stain
macrophageskupff
cell
endotheli
cell
immunofluoresc
posit
mhc
class
ii
viral
inhibit
studi
mous
periton
macrophag
isol
balbcj
mice
outlin
previous
cell
preincub
presenc
hrc
moll
conjug
ribavirin
free
ribavirin
moll
hour
infect
pfu
moi
macrophag
harvest
hour
infect
analyz
viral
titer
describ
hepatocyt
isol
balbcj
mice
preincub
presenc
increas
concentr
either
hrc
ribavirin
moll
hour
medium
replac
fresh
medium
follow
infect
moi
period
hour
cell
harvest
measur
viral
titer
carri
manner
similar
describ
macrophag
cellbind
studi
mous
periton
macrophag
isol
balbcj
mice
outlin
previous
cell
place
ml
polypropylen
tube
complex
hphb
prepar
fresh
assay
combin
fluoresceinlabel
haptoglobin
fhp
hb
molar
ratio
incub
hour
room
temperatur
rt
dark
two
hundredmicrolit
aliquot
dilut
rmpi
fb
ad
macrophag
incub
hour
cell
pellet
rpm
minut
wash
resuspend
pb
macrophag
prestimul
either
moi
rmpi
fb
hour
dexamethason
rmpi
fb
hour
control
rmpi
fb
cell
wash
resuspend
rpmi
fb
place
hour
incub
fhphb
compound
hour
bind
fluoresc
label
protein
macrophag
detect
use
cytom
fc
mpl
flow
cytomet
analyz
cytometr
rxp
analysi
softwar
beckman
coulter
fullerton
ca
supernat
collect
treat
cell
concentr
assay
elisa
monoclon
hamster
antimurin
ab
genzym
boston
coat
elisa
plate
overnight
wash
tri
buffer
ph
plate
block
l
bovin
serum
albumin
well
hour
rt
wash
l
standard
sampl
ad
incub
rt
hour
subsequ
l
polyclon
rabbit
antimous
ab
genzym
ad
well
plate
incub
overnight
goat
antirabbit
igg
alkalin
phosphatas
l
jackson
immunoresearch
laboratori
west
grove
pa
ad
plate
incub
rt
hour
wash
l
diflusin
phosphat
substrat
buffer
ad
plate
incub
addit
minut
rt
shake
plate
read
cyber
fluor
beckman
instrument
fullerton
ca
unit
assay
comparison
mous
standard
genzym
supernat
collect
treat
cell
concentr
assay
abil
supernat
inhibit
support
prolifer
wehi
cell
cultur
incub
hour
humidifi
co
atmospher
puls
ci
h
thymidin
sp
act
cimmol
amersham
arlington
height
il
harvest
hour
later
onto
glass
fiber
filter
total
cellassoci
radioact
measur
beckman
scintil
counter
bioassay
data
express
nanogramsmillilit
deriv
standard
curv
mous
recombin
genzym
mice
femal
balbcj
mice
week
age
purchas
charl
river
laboratori
st
constant
quebec
canada
hous
microisol
cage
anim
facil
toronto
gener
hospit
mice
fed
standard
laboratori
chow
diet
water
ad
libitum
anim
divid
treatment
group
n
mice
per
group
group
control
pfumous
group
receiv
hrc
via
tail
vein
inject
mg
conjug
ribavirinkgday
start
day
daili
thereaft
pfumous
group
receiv
ribavirin
tail
vein
inject
describ
sidwel
et
al
mgkgday
start
day
daili
thereaft
pfumous
group
control
uninfect
mice
control
anim
given
daili
inject
l
pb
via
tail
vein
mice
infect
intraperiton
inject
plaqueform
unit
pfu
l
pb
mice
kill
day
analyz
evid
hepat
liver
biochemistri
alanin
transaminas
alt
hematolog
disturb
hemoglobin
hematocrit
white
blood
cell
count
platelet
count
renal
dysfunct
blood
urea
nitrogen
clinic
behavior
effect
treatment
ribavirin
hrc
liver
diseas
determin
monitor
mice
twice
daili
subject
sign
clinic
behavior
includ
abnorm
fur
textur
decreas
activ
increas
respir
presenc
tremor
develop
decreas
activ
increas
fur
ruffl
difficulti
respir
increas
shake
sign
poor
clinic
behavior
grade
scale
indic
mark
presenc
abnorm
normal
composit
score
paramet
calcul
perform
independ
examin
blind
treatment
regimen
attempt
minim
bia
collect
blood
tissu
day
sacrific
mice
anesthet
use
halothan
follow
percutan
cardiac
punctur
collect
blood
edtacontain
microtain
tube
bectondickinson
franklin
lake
nj
previous
describ
liver
remov
time
death
describ
follow
section
viral
titer
effect
ribavirin
hrc
viral
replic
vivo
vitro
studi
determin
standard
plaqu
assay
vitro
studi
monolay
periton
macrophag
hepatocyt
balbcj
mice
pretreat
ribavirin
hrc
medium
rpmi
addit
viru
moi
hour
post
infect
cell
harvest
subject
one
cycl
freez
thaw
assay
viral
titer
monolay
cell
vivo
studi
section
liver
tissu
weigh
snap
frozen
tissu
collect
analysi
subsequ
tissu
thaw
homogen
dounc
homogen
dulbecco
modifi
essenti
medium
supplement
fb
mmoll
glutamin
homogen
assay
viru
use
plaqu
assay
describ
previous
hphb
free
hb
shown
hepatocyt
macrophag
toxic
viral
inhibitori
effect
concentr
studi
data
shown
liver
histolog
time
sacrific
liver
remov
weigh
fix
buffer
formalin
minimum
hour
tissu
process
paraffinembed
routin
methodolog
section
thick
stain
hematoxylin
eosin
martiu
scarlet
blue
addit
liver
immunostain
fibrin
use
nex
immunostain
method
section
liver
recov
mice
per
group
time
point
score
extent
necrosi
fibrin
deposit
surfac
liver
examin
equal
instanc
correspond
contigu
histolog
field
low
magnif
blood
analysi
blood
analyz
hemoglobin
hematocrit
prothrombin
time
partial
thromboplastin
time
use
portabl
hemochron
jr
ii
microcoagul
system
intern
technidyn
corpor
edison
nj
sera
anim
analyz
quantit
measur
liver
cell
necrosi
serum
alt
univers
health
network
central
laboratori
previous
describ
blood
sugar
electrolyt
blood
urea
nitrogen
analyz
sampl
use
ektachem
analyz
depart
biochemistri
univers
health
network
previous
describ
lack
interfer
biochemistri
test
address
includ
sampl
normal
sera
spike
differ
concentr
hphbrv
conjug
complex
unus
sera
frozen
store
addit
test
requir
statist
analysi
statist
analysi
conduct
student
test
p
valu
less
consid
statist
signific
result
report
mean
sd
least
separ
experi
perform
triplic
previou
report
suggest
infect
mediat
viral
replic
macrophag
replic
hepatocyt
therefor
experi
perform
examin
efficaci
hrc
directli
viral
replic
isol
macrophag
cell
preincub
either
pb
control
free
ribavirin
moll
hrc
moll
conjug
ribavirin
hour
infect
viru
concentr
ribavirin
chosen
base
previou
report
effect
ribavirin
viral
replic
isol
macrophag
cultur
doserespons
curv
conduct
cell
harvest
hour
viral
titer
measur
describ
previous
ad
concentr
moll
free
ribavirin
effect
reduc
viral
titer
contrast
lower
dose
ribavirin
moll
conjug
hb
inhibit
replic
fig
degre
inhibit
signific
repres
approxim
decreas
viral
titer
log
compar
pbsand
ribavirintr
cell
fig
inhibit
respons
hrc
attribut
toxic
effect
cell
demonstr
trypan
blue
exclus
data
shown
strike
effect
hrc
viral
replic
may
attribut
target
deliveri
hrc
via
hemoglobinhaptoglobin
receptor
locat
surfac
cell
monocytemacrophag
lineag
previou
studi
shown
express
increas
respons
glucocorticoid
dexamethason
stimul
measur
hbbind
macrophag
cultur
periton
macrophag
fluoresceinlabel
hphb
fhphb
bind
hphb
compar
unstimul
dexamethasonestimul
macrophag
fig
bind
increas
dosedepend
fashion
case
howev
hphb
bind
tend
greater
dexamethasonetr
macrophag
data
consist
previou
report
dexamethason
induc
express
surfac
macrophag
experi
perform
test
abil
hrc
modul
immun
respons
macrophag
ribavirin
shown
alter
product
proinflammatori
cytokin
mous
periton
macrophag
supernat
macrophag
analyz
product
proinflammatori
cytokin
macrophag
produc
significantli
higher
level
respons
infect
comparison
basal
valu
fig
ribavirin
moll
hrc
moll
conjug
ribavirin
significantli
inhibit
product
macrophag
compar
control
compound
prevent
increas
cytokin
level
baselin
howev
effect
achiev
use
much
lower
dose
th
ribavirin
hrc
conjug
form
free
ribavirin
form
experi
perform
examin
efficaci
hrc
directli
viral
replic
isol
hepatocyt
hepatocyt
isol
balbcj
mice
preincub
presenc
increas
concentr
either
hrc
ribavirin
hour
incub
cell
wash
time
remov
unbound
hrc
ribavirin
infect
kept
cultur
hour
result
experi
suggest
hrc
effect
free
ribavirin
inhibit
viral
replic
fig
inhibit
viral
replic
hrc
approxim
moll
conjug
ribavirin
compar
inhibit
concentr
free
ribavirin
inhibit
hrc
free
ribavirin
similar
moll
drug
higher
anoth
measur
improv
efficaci
abil
hrc
inhibit
cytopath
effect
viru
indic
format
hepat
cell
fusion
syncytia
respons
viral
infect
fig
compar
normal
uninfect
hepatocyt
fig
untreat
hepatocyt
develop
virusinduc
patholog
condit
evidenc
presenc
syncytia
within
hour
infect
fig
pretreat
hepatocyt
hrc
gml
result
mark
reduct
virusinduc
patholog
condit
fig
contrast
concentr
moll
free
ribavirin
effect
reduc
format
syncytia
macrophag
fig
result
vitro
studi
demonstr
improv
efficaci
hrc
free
ribavirin
therefor
seri
experi
perform
evalu
vivo
efficaci
hrc
cours
fulmin
hepat
failur
induc
suscept
balbcj
mice
balbcj
mice
infect
viru
treat
pb
free
ribavirin
hrc
treatment
mice
examin
daili
effect
surviv
clinic
behavior
one
mous
untreat
group
mice
ribavirin
tabl
contrast
surviv
enhanc
ribavirinand
hrc
mice
fig
associ
increas
surviv
reduct
liver
necrosi
indic
decreas
level
liver
alt
alt
max
iul
ribavirin
iul
hrc
tabl
liver
assay
determin
viral
titer
day
viral
titer
risen
minim
detect
limit
assay
although
signific
differ
group
observ
fig
day
pbstreat
mice
die
measur
viral
titer
liver
ribavirinand
hrc
mice
day
demonstr
reduct
viral
replic
hrc
anim
compar
ribavirin
group
fig
composit
clinic
score
fig
obtain
combin
clinic
score
measur
symptom
mice
observ
symptom
abnorm
fur
textur
fig
respir
fig
tremor
fig
case
pbstreat
mice
observ
sever
symptom
ribavirin
hrc
therapi
improv
clinic
score
mice
howev
day
hrc
therapi
improv
clinic
score
greater
degre
ribavirin
alon
clinic
mice
treat
ribavirin
develop
clinic
symptom
compat
drug
toxic
ongo
viral
infect
contrast
hrc
mice
maintain
improv
score
behavior
categori
end
studi
fig
hematocrit
hemoglobin
level
tabl
measur
assess
effect
hrc
known
hemolyt
toxic
ribavirin
hemoglobin
level
hrc
mice
greater
control
uninfect
mice
suggest
dose
hb
form
hrc
contribut
significantli
total
blood
hb
concentr
hrc
administr
provid
addit
mg
hb
daili
provid
modest
increas
total
hb
base
total
hb
concentr
gl
control
untreat
mice
hb
level
hrc
mice
statist
higher
ribavirintr
mice
postinfect
p
statist
differ
uninfect
control
mice
untreat
mice
day
onward
tabl
suggest
decreas
blood
total
hb
hematocrit
ribavirintr
mice
cours
studi
addit
level
blood
urea
nitrogen
higher
bicarbon
level
lower
significantli
lower
ribavirintr
mice
compar
hrc
mice
suggest
ribavirin
treatment
result
disturb
metabol
function
mice
collect
data
suggest
conjug
ribavirin
carrier
protein
hemoglobin
reduc
system
toxic
associ
free
ribavirin
addit
improv
overal
surviv
clinic
behavior
ribavirin
hrc
reduc
histolog
sign
associ
infect
liver
remov
examin
histolog
evid
necrosi
fibrin
deposit
fig
liver
recov
pbstreat
mice
show
greater
necrosi
day
postinfect
contrast
ribavirin
hrc
infect
mice
show
mark
reduct
histolog
evid
hepat
necrosi
maximum
level
hepat
necrosi
fig
intens
immunostain
fibrin
significantli
reduc
section
liver
ribavirinand
hrc
mice
fig
histolog
grade
liver
section
variou
treatment
group
illustr
greatest
intens
fibrin
stain
observ
pbstreat
mice
day
infect
fig
intens
correl
intens
observ
clinic
symptom
fig
contrast
liver
ribavirintr
mice
neg
sign
necrosi
fibrosi
although
complet
free
diseas
liver
mice
show
signific
decreas
hepat
necrosi
fibrin
deposit
compar
pbstreat
mice
fig
ribavirin
use
combin
interferon
treatment
acut
chronic
hepat
c
howev
effect
limit
hemolyt
toxic
requir
dose
reduct
discontinu
portion
treatment
popul
renal
clearanc
need
maintain
sustain
virolog
respons
svr
larg
daili
dose
ribavirin
necessari
sustain
benefici
respons
investig
efficaci
target
form
ribavirin
hrc
murin
hepat
viru
strain
assess
benefit
hemoglobinconjug
ribavirin
compar
free
ribavirin
caus
spectrum
liver
diseas
mice
includ
fulmin
hepat
liver
failur
death
vitro
vivo
experi
report
show
hrc
effect
infect
higher
dose
free
ribavirin
result
vitro
experi
macrophag
support
use
hemoglobin
target
drug
therapi
vivo
viral
replic
macrophag
prerequisit
gain
access
liver
parenchym
cell
replic
reduc
macrophag
treat
hrc
contrast
macrophag
treat
approxim
higher
dose
free
ribavirin
effect
due
drug
toxic
macrophag
incub
either
hrc
ribavirin
viabl
shown
exclus
trypan
blue
free
ribavirin
produc
improv
viral
titer
compar
reduct
viral
titer
produc
hrc
viral
infect
macrophag
also
activ
immun
cascad
mediat
cytokin
product
product
proinflammatori
cytokin
includ
increas
macrophag
compar
uninfect
macrophag
deliveri
hrc
macrophag
via
hemoglobinhaptoglobin
receptor
allow
direct
target
antivir
therapeut
import
member
innat
immun
system
recent
studi
demonstr
increas
express
liver
patient
acut
hepat
compar
chronic
hepat
noninfect
individu
increas
presenc
attribut
increas
number
activ
macrophag
liver
affect
individu
benefit
target
macrophag
support
demonstr
significantli
greater
reduct
viral
titer
compar
reduct
product
proinflammatori
cytokin
use
lower
dose
drug
conjug
form
compar
free
drug
result
present
studi
also
demonstr
enhanc
antivir
activ
hrc
isol
mous
hepatocyt
infect
viru
free
ribavirin
ineffect
reduc
viral
replic
dose
moll
contrast
hepatocyt
incub
concentr
drug
form
hrc
signific
reduct
viral
replic
observ
dose
hrc
requir
inhibit
viral
replic
micromolar
moll
isol
hepatocyt
wherea
similar
viral
inhibit
cultur
macrophag
moll
concentr
ribavirin
requir
even
concentr
moll
signific
inhibit
viral
growth
seen
isol
hepatocyt
wherea
macrophag
concentr
inhibit
seen
explan
find
differ
bind
drug
intracellular
process
rate
degrad
compound
could
account
differ
releas
ribavirin
monophosph
might
explain
enhanc
antivir
activ
hepatocyt
howev
ribavirin
releas
hrc
shown
free
ribavirin
monophosphoryl
form
hrc
also
inhibit
viral
cytopath
effect
syncytia
format
wherea
free
ribavirin
effect
specif
hrc
neither
hbhp
complex
alon
hbrv
conjug
alon
inhibitori
data
shown
taken
togeth
find
suggest
receptormedi
process
underli
improv
activ
hrc
compar
free
drug
although
express
hepatocyt
hemoglobin
hemoglobinhaptoglobin
shown
bind
hepatocyt
receptormedi
fashion
although
hepatocyt
receptor
identifi
effect
hrc
also
compar
free
ribavirin
vivo
model
viral
hepat
control
mice
die
within
day
infect
massiv
liver
necrosi
hrc
free
ribavirin
improv
surviv
compar
untreat
control
hrc
treat
mice
exhibit
improv
clinic
behavior
wherea
mice
receiv
free
ribavirin
show
symptom
consist
drug
toxic
ongo
viral
infect
despit
better
histolog
free
ribavirin
group
addit
hrc
maintain
hematocrit
valu
near
baselin
compar
decreas
hematocrit
observ
free
ribavirin
group
hemolyt
effect
ribavirin
normal
occur
week
daili
dose
human
whether
appar
avoid
effect
mice
directli
relat
known
toxic
ribavirin
unknown
nevertheless
although
exact
mechan
benefici
effect
hrc
known
data
present
suggest
coupl
ribavirin
hemoglobin
improv
safeti
efficaci
ribavirin
target
deliveri
ribavirin
infect
cell
day
infect
ribavirintr
hrc
mice
aliv
howev
liver
harvest
mice
treat
hrc
significantli
lower
viral
titer
liver
mice
treat
approxim
free
ribavirin
data
vitro
experi
suggest
overal
decreas
liver
viral
titer
like
attribut
decreas
viral
titer
macrophag
hepatocyt
respons
hrc
hemoglobin
thu
serv
natur
drug
carrier
target
therapi
receptorbear
cell
product
proinflammatori
cytokin
markedli
reduc
ribavirin
hrc
macrophag
vitro
fibrin
deposit
liver
respons
activ
immun
coagul
system
involv
mediat
shown
involv
immun
respons
hcv
fibrosi
progress
murin
model
overexpress
induc
sever
liver
damag
liver
harvest
mice
treat
ribavirin
hrc
demonstr
significantli
lower
level
fibrin
deposit
necrosi
compar
pbstreat
mice
therefor
reduct
proinflammatori
cytokin
product
like
contribut
overal
improv
liver
histolog
overal
effect
hrc
infect
vivo
demonstr
conjug
target
deliveri
ribavirin
form
hrc
produc
enhanc
antivir
activ
signific
improv
aspect
respons
infect
compar
untreat
infect
mice
provid
respons
compar
better
higher
dose
free
drug
combin
vitro
find
result
present
provid
import
proofofconcept
effect
hrc
target
drug
agent
use
hemoglobin
collect
result
suggest
target
ribavirin
may
allow
enhanc
clinic
virolog
benefit
set
stage
clinic
trial
design
treat
patient
infect
hepat
c
although
result
present
suggest
identif
new
form
therapi
chronic
hepat
c
data
suggest
target
deliveri
ribavirin
macrophag
hepatocyt
reduc
mani
system
side
effect
produc
free
ribavirin
therefor
sustain
hrc
therapi
could
potenti
allevi
system
side
effect
hemolyt
anemia
normal
result
prematur
cessat
ribavirin
therapi
undertook
studi
examin
potenti
benefit
hemoglobinconjug
ribavirin
compound
hrc
prevent
amelior
liver
injuri
caus
murin
hepat
viru
strain
shown
hrc
effect
infect
caus
spectrum
liver
diseas
mice
includ
fulmin
hepat
liver
failur
death
also
found
mark
antivir
antiinflammatori
effect
hrc
macrophag
presum
mediat
cellspecif
uptak
effect
appear
relat
directli
amelior
liver
injuri
infect
mice
experi
perform
provid
evid
hrc
compound
biochem
histolog
efficaci
amelior
liver
injuri
caus
